Merck And Jiangsu Hengrui Pharmaceuticals Entered Into An Exclusive License Agreement For HRS-5346, An Investigational Oral Small Molecule Lipoprotein(a) Inhibitor Currently In A Phase 2 Trial In China, Hengrui Pharma Will Receive An Upfront Payment...

BenzingaMar 25 06:47 ET

BYD's Q4 Net income increased by 73.1% year-on-year, reaching a new high, proposing a distribution of 39.74 yuan per share | Earnings Reports insights.

BYD's sales last year exceeded 100 billion USD for the first time in history, surpassing Tesla; the sales of pure electric vehicles reached 1.76 million units for the year, slightly lower than Tesla, while the total sales of cars, including hybrids, reached 4.272 million units, a year-on-year increase of 41%.

wallstreetcnMar 24 20:23 ET

Automakers Earnings Reports season | Revenue hitting a record high, net profit closing in on Tesla. BYD enters a period of intensive product launches after achieving its best Earnings Reports ever.

① BYD's total revenue for the full year of 2024 reached 777.102 billion yuan, a year-on-year increase of 29.02%; the net income attributable to shareholders of the listed company reached 40.254 billion yuan, a year-on-year increase of 34%. ② In 2024, BYD's cumulative sales reached 4.2721 million vehicles, a significant year-on-year increase of 41.26%. ③ BYD's debt-to-asset ratio for 2024 was 77.55%, slightly down from the end of the previous year.

cls.cnMar 24 11:13 ET

Real reversal or short-term warming? A surge in distributed photovoltaic installations is happening, with some Dealers claiming to have encountered "order cancellations".| Fax

① Under the rush of photovoltaic installations, an outbreak of demand has led to insufficient supply, causing conflicts in production and sales, with some Dealers claiming that they have had their orders "canceled" by component manufacturers; ② Dealers state that their current focus is entirely on the rush of installations for the two key deadlines of April 30 and May 31, feeling overworked and primarily concentrating on installation; ③ Analysis suggests that the current emphasis on controlling production capacity in the photovoltaic Industry has reached an unprecedented level, which will effectively alleviate the situation of oversupply.

cls.cnMar 24 10:38 ET

The FDA has once again delayed the approval for Jiangsu Hengrui Pharmaceuticals' PD-1 combination product.

Once again, it is a production compliance issue.

wallstreetcnMar 21 07:03 ET

The "Double Ai" therapy has encountered obstacles again in its launch in the USA. Jiangsu Hengrui Pharmaceuticals responded that they will "quickly resubmit the listing application after confirming the reasons."

① The "Double Ai" therapy has received a complete response letter from the FDA upon the second submission of the application; ② Jiangsu Hengrui Pharmaceuticals responded to reporters stating: they will promptly resubmit the application for market approval after confirming the reasons; ③ Experts say, "This is just a minor setback, production-related issues are easy to resolve."

cls.cnMar 21 06:32 ET